Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    Gaxilose

    go.drugbank.com/drugs/DB12767
    ApprovedWithdrawn

    Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance.

  2. Drug

    GC5107

    go.drugbank.com/drugs/DB17604
    Investigational

    GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.

  3. Drug

    Ethylestrenol

    go.drugbank.com/drugs/DB01493
    ApprovedWithdrawn

    An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]

  4. Drug

    Parethoxycaine

    go.drugbank.com/drugs/DB19380
    ApprovedWithdrawn

    Parethoxycaine is a local anesthetic that was previously approved in the US.

  5. Drug

    Turofexorate isopropyl

    go.drugbank.com/drugs/DB12719
    Investigational

    Fxr 450 is under investigation in clinical trial NCT00509756 (Study Evaluating Turofexorate isopropyl in Healthy Japanese Men).

  6. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  7. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  8. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma) … ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc).

  9. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication

  10. Drug

    Foscarbidopa

    go.drugbank.com/drugs/DB16171
    Approved

    Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult